At C-Lab, our mission is to drive the fight against cancer by offering innovative diagnostic solutions to both doctors and patients.

One such innovation is the liquid biopsy test—a non-invasive method for cancer detection and monitoring using the ddPCR technology.

By offering innovative diagnostic solutions like liquid biopsy, we provide our patients with the most advanced diagnostics in the region, reinforcing our commitment to transforming cancer care and improving outcomes.

How does this innovation redefine cancer care?

Facilitates early detection, improving outcomes.

Enhances real-time monitoring of therapeutic efficacy.

Reduces relapse risks through residual disease detection.

Provides oncologists with actionable insights for tailored treatment plans.

Zaahirah Moreea Coowar, Head of Operational Excellence and Specialised Lab, highlights: “At C-Lab, we are commited to transforming cancer diagnostics by integrating cutting-edge technologies into our services. The acquisition of ddPCR technology, which enables highly sensitive liquid biopsy tests, significantly enhances our ability to improve patient prognosis and diagnosis by providing oncologists with reliable results. Additionally, our advanced NGS technology complements this approach, offering comprehensive solutions throughout the cancer care pathway and enabling personalised treatment plans tailored to each patient’s needs.”